2016 Press Releases

Keyword Search
 
2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
12/03/16Takeda and Seattle Genetics Report Positive Phase 3 ALCANZA Clinical Trial Data of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma
– Data will be presented in an oral session at the annual American Society of Hematology (ASH) meeting on Saturday, December 3 at 2:15 p.m. PT –– Trial achieved highly statistically significant improvements in rate of objective response lasting at least four months, median progression-free survival and overall response rate, and decrease in symptom burden in ADCETRIS arm; Safety profile associated with ADCETRIS was generally consistent with the existing prescribing information – CAMBRIDG... 
Printer Friendly Version
12/03/16Seattle Genetics Presents Phase 1b Data from Vadastuximab Talirine (SGN-CD33A; 33A) in Combination with Standard of Care in Frontline Acute Myeloid Leukemia at ASH Annual Meeting
-Clinical Data Featured in Press Program and Oral Presentation Indicate 33A is Well Tolerated in Combination with 7+3 Induction Therapy in Younger Newly Diagnosed AML Patients- -Antileukemic Activity Data Show Remission Rate of 76 Percent, with 78 Percent of Those Remissions Negative for Minimal Residual Disease- SAN DIEGO--(BUSINESS WIRE)--Dec. 3, 2016-- Seattle Genetics, Inc. (NASDAQ: SGEN), a global biotechnology company, today ... 
Printer Friendly Version
12/03/16Seattle Genetics Presents Data from Phase 2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Diffuse Large B-cell Lymphoma at ASH Annual Meeting
SAN DIEGO--(BUSINESS WIRE)--Dec. 3, 2016-- Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today presented data from a phase 2 clinical trial evaluating ADCETRIS (brentuximab vedotin) combination therapy in frontline diffuse large B-cell lymphoma (DLBCL) at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Diego, California, December 3-6, 2016. ADCETRIS is an antibody-drug ... 
Printer Friendly Version
11/29/16Seattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 29, 2016-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that the company will webcast an investor and analyst event on Monday, December 5, 2016 during the 58th American Society of Hematology (ASH) Annual Meeting in San Diego, CA. Members of the Seattle Genetics management team and industry experts will discuss data being presented at the conference, including from the ADCETRIS® (brentuximab vedotin) and ... 
Printer Friendly Version
11/10/16Seattle Genetics Receives FDA Breakthrough Therapy Designation for ADCETRIS® (Brentuximab Vedotin) in Mycosis Fungoides and Primary Cutaneous Anaplastic Large Cell Lymphoma
-Submission of Supplemental Biologics License Application for ADCETRIS in CD30-Expressing CTCL Planned in First Half of 2017- -Positive Phase 3 ALCANZA Trial Data Evaluating ADCETRIS in CTCL to be Highlighted in Oral Presentation at Upcoming American Society of Hematology Annual Meeting- BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 10, 2016-- Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced that th... 
Printer Friendly Version
11/08/16Seattle Genetics and Takeda Complete Enrollment of Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Mature T-cell Lymphoma
-ECHELON-2 Trial Represents Key Component of Late-Stage Clinical Development Strategy to Establish ADCETRIS as Foundation of Care for CD30-Expressing Lymphomas- -Data from ECHELON-2 Phase 3 Trial Expected in 2017 to 2018 Timeframe- BOTHELL, Wash. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 8, 2016-- Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced completion of patient ... 
Printer Friendly Version
11/03/16Seattle Genetics Announces ASH 2016 Abstracts Highlighting Company’s Expanding Global Leadership in the Development of Innovative Antibody-Drug Conjugates
Oral Presentation on Phase 3 ALCANZA Trial in CD30-Expressing Cutaneous T-Cell Lymphoma Breadth of Data on ADCETRIS® (Brentuximab Vedotin), Vadastuximab Talirine (SGN-CD33A) and Other Pipeline Programs Demonstrate Company’s Commitment to Improve Therapeutic Options in Oncology BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 3, 2016-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that 18 abstracts including eight oral presentations ... 
Printer Friendly Version
11/01/16Seattle Genetics to Present at Credit Suisse 25th Annual Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 1, 2016-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay Siegall, Ph.D., President and Chief Executive Officer, will present at the Credit Suisse 25th Annual Healthcare Conference on Tuesday, November 8, at 10:00 a.m. Mountain Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. ... 
Printer Friendly Version
10/27/16Seattle Genetics Reports Third Quarter 2016 Financial Results
-Third Quarter 2016 Revenues Were $106.3 Million, Including Record $70.1 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Sales- -Broad Presence at Upcoming American Society of Hematology (ASH) Annual Meeting, Including an Oral Presentation on the ALCANZA Phase 3 Trial and Four Oral Presentations on Vadastuximab Talirine (SGN-CD33A)- -Conference Call Today at 4:30 p.m. ET- BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 27,... 
Printer Friendly Version
10/20/16Seattle Genetics Demonstrates Commitment to Improve Hodgkin Lymphoma Treatment Paradigm through Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at ISHL 2016
-ADCETRIS Data Featured in 21 Presentations Broadly Across HL Disease Settings- -Data from Multiple Presentations Support Goal to Establish ADCETRIS as the Foundation of Care for classical HL- BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 20, 2016-- Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted multiple data presentations at the 10th International Symposium on Hodgkin Lymphoma (ISHL) taking place in Cologne, Germany, O... 
Printer Friendly Version
10/07/16Seattle Genetics and Agensys, an Affiliate of Astellas, Highlight Promising Enfortumab Vedotin (ASG-22ME) and ASG-15ME Phase 1 Data in Metastatic Urothelial Cancer at 2016 ESMO Congress
-Objective Response Rates Presented for Both Antibody-Drug Conjugate Programs- -Enfortumab Vedotin Demonstrates 59 Percent Objective Response Rate at Recommended Phase 2 Dose of 1.25 mg/kg, Supporting Advancement of the Development Program- BOTHELL, Wash. & NORTHBROOK, Ill.--(BUSINESS WIRE)--Oct. 7, 2016-- Seattle Genetics, Inc. (NASDAQ: SGEN) and Agensys, an affiliate of Astellas, today presented updated clinical data for e... 
Printer Friendly Version
10/06/16Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2016 Financial Results on October 27, 2016
BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 6, 2016-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its third quarter 2016 financial results on Thursday, October 27 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE acce... 
Printer Friendly Version
10/04/16Seattle Genetics Announces Executive Promotions and Leadership Appointment
-Vaughn B. Himes, Ph.D., Promoted to Chief Technical Officer- -Dennis Benjamin, Ph.D., Promoted to Senior Vice President, Translational Research- -Robert J. Lechleider, M.D., Named Senior Vice President, Clinical Development- BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 4, 2016-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced two executive promotions and an executive appointment to the company’s clinical development lead... 
Printer Friendly Version
09/19/16Seattle Genetics Initiates Phase 1 Trial of SGN-CD123A for Patients with Relapsed or Refractory Acute Myeloid Leukemia
-SGN-CD123A, A Novel Antibody-Drug Conjugate (ADC), Represents Seattle Genetics’ Second Clinical ADC Program Focused on AML- - Preclinical Data Showing Potent Anti-Leukemic Activity of SGN-CD123A Presented at the 2015 American Society of Hematology Annual Meeting- BOTHELL, Wash.--(BUSINESS WIRE)--Sep. 19, 2016-- Seattle Genetics, Inc. (NASDAQ: SGEN) today announced enrollment of the first patient in a multicenter phase 1... 
Printer Friendly Version
09/06/16Seattle Genetics to Present at Morgan Stanley Global Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Sep. 6, 2016-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 13, at 9:10 a.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. About Seattle Genetics Seattle ... 
Printer Friendly Version
08/01/16Takeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma
-Randomized Phase 3 Clinical Trial with ADCETRIS Met Primary Endpoint, Demonstrating Highly Statistically Significant Improvement in Rate of Objective Response Lasting at Least Four Months- -Abstract to be Submitted to ASH for Presentation at the 2016 Annual Meeting- BOTHELL, Wash. & CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Aug. 1, 2016-- Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ:SGEN) today an... 
Printer Friendly Version
07/26/16Seattle Genetics Reports Second Quarter 2016 Financial Results
-Second Quarter 2016 Revenues Were $95.4 Million, Including Record $66.2 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Sales- -Top-Line Data from ADCETRIS Phase 3 ALCANZA Trial Expected in Third Quarter of 2016- -Conference Call Today at 4:30 p.m. ET- BOTHELL, Wash.--(BUSINESS WIRE)--Jul. 26, 2016-- Seattle Genetics, Inc. (NASDAQ: SGEN) today reported financial results for the second quarter ended... 
Printer Friendly Version
07/18/16Seattle Genetics and Takeda Announce Publication of Final Data from ADCETRIS® (Brentuximab Vedotin) Monotherapy Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Classical Hodgkin Lymphoma in Blood
-Estimated Five-Year Overall Survival Rate was 41 Percent and Five-Year Progression-Free Survival Rate was 22 Percent--Patients Who Achieved a Complete Remission Had Estimated Five-Year Overall Survival of 64 Percent and Five-Year Progression-Free Survival of 52 Percent-BOTHELL, Wash., CAMBRIDGE, Mass. and OSAKA, Japan, July 18, 2016 – Seattle Genetics, Inc. (NASDAQ:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced the final data of the ADCETRIS (brentuximab vedotin) mon... 
Printer Friendly Version
07/13/16Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2016 Financial Results on July 26, 2016
BOTHELL, Wash.--(BUSINESS WIRE)--Jul. 13, 2016-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its second quarter 2016 financial results on Tuesday, July 26 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access... 
Printer Friendly Version
07/06/16Seattle Genetics Announces European Commission Approval of ADCETRIS® (Brentuximab Vedotin) as Consolidation Treatment in Post-Transplant Hodgkin Lymphoma
-Marketing Authorization Granted Based on Phase 3 AETHERA Clinical Trial Results- -Label Expansion Represents Third Indication for ADCETRIS in the European Union; AETHERA is the First of Four Phase 3 Clinical Trials Intended to Broaden the Global Use of ADCETRIS in CD30-Expressing Lymphomas- BOTHELL, Wash.--(BUSINESS WIRE)--Jul. 6, 2016-- Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that its collaborator Takeda Pharmaceu... 
Printer Friendly Version
06/11/16Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data in Acute Myeloid Leukemia (AML) at the 21st Congress of the European Hematology Association
-Phase 1 Clinical Data Featured in Press Program and Oral Presentation Demonstrate 76 Percent Objective Response Rate, Including a 41 Percent Complete Remission Rate, in Newly Diagnosed AML Patients Treated with 33A Combination Therapy- -Data Support Recently Initiated Phase 3 CASCADE Study Evaluating 33A in Combination with Hypomethylating Agents in AML Patients- COPENHAGEN, Denmark, June 11, 2016 /PRNewswire/ -- Seattle Genetics, Inc. (NASDAQ: SGEN) today highlighted data at the 21s... 
Printer Friendly Version
06/06/16Seattle Genetics and Astellas Present ASG-15ME and Enfortumab Vedotin Phase I Clinical Data in Metastatic Urothelial Cancer at ASCO Annual Meeting
-Clinical Data Indicating Antitumor Activity Presented from Two Antibody-Drug Conjugate Programs- CHICAGO & TOKYO--(BUSINESS WIRE)--Jun. 6, 2016-- Seattle Genetics, Inc. (NASDAQ:SGEN) and Astellas Pharma Inc. (TOKYO:4503) today presented first clinical data for ASG-15ME and enfortumab vedotin (ASG-22ME) at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting being held June 3-7, 2016, in Chicago, IL. This Smart New... 
Printer Friendly Version
05/25/16Seattle Genetics Initiates Pivotal Phase 3 Trial of Vadastuximab Talirine (SGN-CD33A) for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
-The Phase 3 Study, Called CASCADE, will Evaluate 33A in Combination with Hypomethylating Agents in Older AML Patients- -Data Presented at the 2015 American Society of Hematology Annual Meeting Demonstrated Encouraging Anti-leukemic Activity and Support Advancing 33A into a Registrational Trial- -Additional 33A Phase 1 Data to be Featured in an Oral Presentation at the European Hematology Association Congress in June 2016- BOTH... 
Printer Friendly Version
05/04/16Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--May 4, 2016-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences. The presentations will be webcast live and available for replay from the Seattle Genetics website at www.seattlegenetics.com in the Investors and News section. Bank of America Merrill Lynch 2016 Health Care Conference Wednesday, May 11, 11:20 a.m. Pacific Ti... 
Printer Friendly Version
04/28/16Seattle Genetics Reports First Quarter 2016 Financial Results
-Record First Quarter 2016 Revenues of $111.2 Million, Including $58.6 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Sales- -Top-Line Data from ADCETRIS Phase 3 ALCANZA Trial Expected in Third Quarter of 2016- -Vadastuximab Talirine (SGN-CD33A) Phase 3 Trial Initiation Planned by Third Quarter of 2016- -First Clinical Data from ASG-15ME and ASG-22ME Phase 1 Trials to be Presented at ASCO- ... 
Printer Friendly Version
04/18/16Seattle Genetics Highlights Data Supporting Antibody-Drug Conjugate and Novel Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 18, 2016-- Seattle Genetics, Inc. (NASDAQ: SGEN) today highlighted multiple data presentations that support several of the company’s antibody-drug conjugate (ADC) and immuno-oncology programs featured at the upcoming 107th Annual Meeting of the American Association for Cancer Research (AACR) being held April 16 through 20, 2016 in New Orleans, LA. The presentations describe preclinical data with SGN-LIV1A and ... 
Printer Friendly Version
04/17/16Seattle Genetics Highlights Novel Antibody-Drug Conjugate (ADC) Technology Advances at the American Association for Cancer Research (AACR) Annual Meeting
-Innovative Research Demonstrates Seattle Genetics’ Leadership in Empowered Antibodies- BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 17, 2016-- Seattle Genetics, Inc. (NASDAQ: SGEN) today highlighted novel antibody-drug conjugate (ADC) technology advances presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR) being held April 16 through 20, 2016 in New Orleans, LA. Data in multiple presentations demonstrat... 
Printer Friendly Version
04/07/16Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2016 Financial Results on April 28, 2016
BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 7, 2016-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter 2016 financial results on Thursday, April 28 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access... 
Printer Friendly Version
03/01/16Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--Mar. 1, 2016-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. Cowen and Company 36th Annual Health Care Conference Tuesday, March 8, 11:20 a.m. Eastern Time, Bost... 
Printer Friendly Version
02/25/16Seattle Genetics Initiates Phase 1 Trial of SGN-CD19B for Patients with B-cell Non-Hodgkin Lymphoma
-SGN-CD19B, A Novel Antibody-Drug Conjugate (ADC) Utilizing Seattle Genetics’ Newest ADC Technology, Demonstrated Strong Preclinical Antitumor Activity in B-cell Malignancies in Data Presented at the 2015 American Society of Hematology Annual Meeting- BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 25, 2016-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced initiation of a phase 1 clinical trial of SGN-CD19B for relapsed or refractory patients with... 
Printer Friendly Version
02/22/16Seattle Genetics Initiates Phase 1/2 Trial of Vadastuximab Talirine (SGN-CD33A) Combination Therapy for Patients with Untreated Myelodysplastic Syndrome (MDS)
-Broad 33A Clinical Development Program Underway in Acute Myeloid Leukemia (AML) and MDS- BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 22, 2016-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced initiation of a phase 1/2 clinical trial of vadastuximab talirine (SGN-CD33A; 33A) in combination with azacitidine (Vidaza) in patients with previously untreated myelodysplastic syndrome (MDS). 33A is an antibody-drug conjugate (ADC) targeted to C... 
Printer Friendly Version
02/09/16Seattle Genetics Reports Fourth Quarter and Year 2015 Financial Results
-Total 2015 Revenues of $336.8 Million, Including $226.1 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Product Sales- -Total 2016 Revenues Expected to Increase to a Range of $390 Million to $430 Million, Including ADCETRIS U.S. and Canada Net Sales of $255 Million to $275 Million- -Vadastuximab Talirine (SGN-CD33A) Phase 3 Trial Initiation Planned by Third Quarter of 2016- -Data from ADCETRIS Phase 3... 
Printer Friendly Version
02/04/16Seattle Genetics Announces Commercial and Regulatory Progress under ADCETRIS® (Brentuximab Vedotin) Collaboration with Takeda
-$20 Million Milestone Payment Triggered by Annual ADCETRIS Net Sales Exceeding $200 Million in Takeda’s Territory During 2015- -European Commission Recently Approved a Type II Label Variation that Includes Data on the Retreatment of Relapsed or Refractory (R/R) Hodgkin lymphoma or R/R Systemic ALCL- BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 4, 2016-- Seattle Genetics, Inc., (Nasdaq: SGEN) today announced that it will receive a one-time $2... 
Printer Friendly Version
01/20/16Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2015 Financial Results on February 9, 2016
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 20, 2016-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its fourth quarter and year 2015 financial results on Tuesday, February 9 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: ... 
Printer Friendly Version
01/05/16Seattle Genetics to Present at the J.P. Morgan Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 5, 2016-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2016 at 2:30 p.m. Pacific Time. Both the presentation and question and answer session that follows at 3:00 p.m. will be webcast live and available for replay from Seattle Genetics’ website at www.seat... 
Printer Friendly Version